- Trial phase
- Phase 3
- Time to market
- If Phase 3 trials succeed, a New Drug Application submission could occur in 2028-2029, with potential FDA approval and launch in 2029-2030 for the IPF chronic cough indication, assuming standard review timelines.
- Why 7/10
- The next hard catalyst is topline data from the Phase 3 OCEAN-1 trial in IPF-related chronic cough, expected in 2027 (within ~6-12 months). Haduvio is Trevi's sole pipeline asset, making this a make-or-break binary for the company, but the exact timing within 2027 is not precisely dated, capping the score at 7.
The next major catalyst is topline data from the Phase 3 OCEAN-1 trial in IPF-related chronic cough, expected in 2027. Positive data would validate the Phase 2b signal and likely drive the stock toward the $28 mean analyst target; negative data would be a severe blow given Haduvio is Trevi's only pipeline asset. A Phase 2 start in non-IPF ILD chronic cough is planned for Q1 2027, and the cash runway into 2030 eliminates near-term financing risk.
Price Chart
Executive Summary
Haduvio (oral nalbuphine ER) is Trevi Therapeutics' sole pipeline asset, an investigational dual-mechanism opioid receptor modulator in Phase 3 development for chronic cough. The drug met its primary endpoint in the Phase 2b CORAL trial (N=165) for IPF-related chronic cough, with results published in JAMA. Two pivotal Phase 3 trials (OCEAN-1 and OCEAN-2) are actively recruiting, with topline data expected in 2027 and 2028. GSK's exit from the chronic cough space after a Phase 3 failure in July 2026 leaves Trevi as the only active developer in its three target indications. The company has a cash runway into 2030, strong institutional backing, and a unanimous analyst Buy consensus with a mean price target implying roughly 90% upside.
How It Works
Haduvio is an extended-release formulation of nalbuphine, a drug that works on opioid receptors in the brain and nervous system to suppress the cough reflex. It acts as a kappa opioid receptor agonist (turns on one type of receptor) and a mu opioid receptor antagonist/partial agonist (blocks or partially activates another type). This dual mechanism is designed to reduce chronic coughing without the full addictive potential of classic opioids like morphine.
Trial Status
Two pivotal Phase 3 trials (OCEAN-1 and OCEAN-2) for IPF-related chronic cough are actively recruiting. OCEAN-1 was initiated in Q2 2026 and OCEAN-2 in Q3 2026. A Phase 2 trial in non-IPF ILD chronic cough is planned to start in Q1 2027. Phase 2b CORAL (IPF cough, N=165) and Phase 2a RIVER (refractory chronic cough, N=66) are both completed with positive results.
The Two-Sided Case
Upcoming Catalysts
- Phase 3 OCEAN-1 topline data expected in 2027
- Phase 3 OCEAN-2 topline data expected in 2028
- Phase 2 start in non-IPF ILD chronic cough planned for Q1 2027
- Potential additional data presentations at medical conferences
Source Filing
The SecBot filing or press-release report that triggered this drug report:
Trevi Therapeutics, Inc. 8-K TRVI ·Originating report